Retatrutide and Hair Loss: Telogen at Higher Weight Loss

    By Trimi Medical Team12 min read

    Hair shedding during significant weight loss is one of the most distressing side effects patients experience, even though it is temporary. With retatrutide producing up to 24.2% body weight loss (Jastreboff et al., NEJM 2023), the risk of telogen effluvium (stress-induced hair shedding) is higher than with medications producing more modest weight loss. Understanding the mechanism, timeline, and prevention strategies helps patients manage this concerning but reversible condition.

    Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. If you experience significant hair loss, consult a dermatologist to rule out other causes.

    Why Weight Loss Causes Hair Loss

    Hair loss from retatrutide is not a direct drug toxicity effect. It is telogen effluvium, a well-known response to physiological stress including rapid weight loss, caloric restriction, nutritional deficiency, and metabolic changes. Hair follicles normally cycle through growth (anagen), transition (catagen), and rest (telogen) phases. When the body experiences significant stress, it shifts more follicles into the telogen (resting) phase simultaneously. About 2-3 months later, these resting hairs shed, causing noticeable thinning.

    The greater the weight loss and the faster it occurs, the more follicles are likely to be affected. At 24% body weight loss, retatrutide may trigger more pronounced telogen effluvium than semaglutide (15%) or tirzepatide (22%) simply because the metabolic stress is greater.

    The Hair Loss Timeline

    TimelineWhat Happens
    Months 1-2Rapid weight loss triggers follicle shift to telogen; no visible shedding yet
    Months 3-4Shedding begins; hair falls out in shower, brush, on pillows
    Months 4-6Peak shedding; most alarming period but typically self-limiting
    Months 6-9Shedding slows; new growth begins as follicles re-enter anagen phase
    Months 9-15Hair density recovers; new hairs growing in

    Nutritional Deficiencies That Worsen Hair Loss

    GLP-1-mediated appetite suppression can lead to inadequate intake of nutrients critical for hair health. Ensure adequate intake of:

    • Protein: Hair is made of keratin (a protein). Less than 50g daily significantly increases shedding risk. Aim for 1.2-1.6g/kg ideal body weight.
    • Iron: Low ferritin (even without anemia) contributes to hair loss. Check levels; supplement if below 40 ng/mL.
    • Zinc: Deficiency causes hair shedding. Found in meat, shellfish, legumes.
    • Biotin (B7): Supports keratin production. 2,500-5,000 mcg daily is commonly recommended.
    • Vitamin D: Deficiency is linked to hair loss. Check levels; supplement if below 30 ng/mL.
    • Omega-3 fatty acids: Support scalp health and follicle function.

    Prevention Strategies

    • Prioritize protein at every meal even when appetite is low
    • Take a comprehensive multivitamin with iron, zinc, biotin, and vitamin D
    • Avoid extreme caloric restriction (do not eat below 1,000 calories daily)
    • Consider a hair-specific supplement containing biotin, saw palmetto, and amino acids
    • Be gentle with hair: Avoid tight hairstyles, excessive heat styling, and chemical treatments
    • Use a wide-tooth comb instead of brushing wet hair
    • Consider minoxidil: Over-the-counter topical minoxidil can stimulate hair growth during shedding phases

    When to See a Dermatologist

    • Hair loss that occurs in patches (could indicate alopecia areata, not telogen effluvium)
    • Shedding that does not improve after 6-9 months
    • Scalp pain, redness, or scarring
    • Eyebrow or eyelash loss (suggests systemic cause)
    • Hair loss that started before retatrutide (may have a separate cause)

    The Good News: It Grows Back

    Telogen effluvium is by definition temporary. Once the body adapts to the new weight and nutritional intake stabilizes, hair follicles re-enter the growth phase. Most patients see hair density return to normal or near-normal within 6-12 months after shedding peaks. The hair that grows back is often healthier than before because the patient's overall nutritional and metabolic health has improved.

    GLP-1 Treatment With Nutritional Guidance

    Trimi provides compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with medical oversight that includes nutritional guidance to minimize side effects like hair loss. Learn how Trimi works.

    Frequently Asked Questions

    Does retatrutide directly cause hair loss?

    Not directly. Hair shedding is caused by the rapid weight loss and caloric restriction, not the medication itself. Any method of rapid weight loss (surgery, extreme dieting) can trigger telogen effluvium.

    Will my hair grow back if I keep taking retatrutide?

    Yes. Telogen effluvium is self-limiting. Even if you continue retatrutide, hair typically regrows as the body adapts to its new weight and nutritional intake stabilizes.

    Should I stop retatrutide because of hair loss?

    Hair shedding alone is not a medical reason to stop treatment. The weight loss benefits typically outweigh temporary hair thinning. Focus on nutrition optimization and patience.

    Does biotin help with GLP-1 hair loss?

    Biotin supplementation may help if you are deficient (which is more likely during caloric restriction). It supports keratin production but is not a cure for telogen effluvium. It works best as part of comprehensive nutritional support.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading

    Does retatrutide cause hair loss?

    Hair loss (telogen effluvium) is a recognized side effect of rapid weight loss — including weight loss from GLP-1 receptor agonist therapy (semaglutide, tirzepatide) and investigational retatrutide. The mechanism: rapid caloric deficit and nutritional changes shock hair follicles into the resting (telogen) phase, leading to diffuse hair shedding approximately 2-4 months after weight loss begins. This is the same mechanism that causes hair loss after surgery, severe illness, or significant emotional stress — it's NOT a direct medication side effect, but rather a downstream consequence of the rapid weight loss the medication enables. Rate: approximately 3-5% of patients on aggressive weight-loss programs experience noticeable hair shedding; the percentage may be higher in real-world populations than in clinical trials. Hair loss is typically temporary and resolves 3-6 months after weight stabilizes, with hair regrowing from the affected follicles. Prevention strategies during GLP-1 therapy: adequate protein intake (target ~30g per meal, ~120g/day during active weight-loss phase) supports lean mass and hair follicle health, sufficient calorie intake (don't drop below 1,200 kcal/day for women, 1,500 kcal/day for men without medical supervision), check iron + vitamin D + zinc + thyroid function (TSH) levels at baseline and again if hair loss occurs. If hair loss persists or worsens beyond 6 months post-weight-stabilization, evaluate for underlying conditions: thyroid dysfunction, iron deficiency anemia, vitamin deficiencies, hormonal imbalances, alopecia. Discuss with your prescribing clinician — temporary hair shedding is rarely a reason to discontinue effective weight-loss therapy, but persistent hair loss warrants investigation. Retatrutide is investigational; same general principles apply.

    ~3-5% rate; temporary; resolves 3-6 mo post-weight-stabilization.
    Mechanism: rapid caloric deficit, not direct medication effect.
    Prevent: 30g protein/meal, ≥1,200-1,500 kcal/day, check iron/D/zinc.

    Key Takeaways

    • Hair loss (telogen effluvium) is a recognized side effect of rapid weight loss — including weight loss from GLP-1 therapy and investigational retatrutide.
    • Mechanism: rapid caloric deficit + nutritional changes shock hair follicles into resting (telogen) phase, leading to diffuse shedding 2-4 months later.
    • Rate: approximately 3-5% of patients on aggressive weight-loss programs; typically temporary and resolves 3-6 months after weight stabilizes.
    • Prevention: adequate protein intake (~30g/meal, ~120g/day during weight loss), sufficient calories (don't go below 1,200 kcal/day), iron + vitamin D + zinc levels checked.
    • If hair loss persists or worsens beyond 6 months post-weight-stabilization, evaluate for thyroid dysfunction, iron deficiency, or other underlying conditions.
    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Dr. Asad Niazi, MD, MPH

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook
    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Eli Lilly and Company (2025). Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration.Read Study
    3. The Endocrine Society (2024). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism.Read Study
    4. American Association of Clinical Endocrinology (2024). AACE Comprehensive Type 2 Diabetes Management Algorithm — Obesity. Endocrine Practice.Read Study

    Was this article helpful?

    Keep Reading

    Retatrutide

    Retatrutide 2mg

    Retatrutide 4mg is the first therapeutic dose — where real weight loss begins. 17.5% average weight loss at this dose alone. Expected results, side effects, and when to consider escalating.

    Retatrutide vs phentermine: 24.2% weight loss with a triple-agonist hormone vs 5-10% with a stimulant. Mechanism, side effects, duration, and why the comparison isn

    Detailed comparison of retatrutide vs tirzepatide: 24.2% vs 22.5% weight loss, mechanism differences, side effects, cost projections, and whether to wait or start now.

    Retatrutide vs Contrave (naltrexone/bupropion): 24.2% weight loss vs 5-8%. How the triple agonist compares to the oral combination pill in efficacy, mechanism, side effects, and cost.

    Start your GLP-1 journey — from $99/mo

    Get Started